Targets › TACR3
3 programs from 2 companies in 11 trials: 6 Phase 2, 3 Phase 3, 2 Phase 1; Oncology, Other, Genitourinary; next expected readout Feb 2027.
Receptor for the tachykinin neuromedin-K (neurokinin B), also able to bind and respond to tachynins substance K/neurokinin A and substance P. The rank order of affinity of this receptor to tachykinins is: neuromedin-K > substance K and substance P. Neuromedin-K binding to its receptor triggers G protein-coupled receptor signaling via activation of G(q) and phosphatidylinositol hydrolysis by phospholipase C.…. (UniProt, P29371)
Open in Phaseline: the race on TACR3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Bayer | Elinzanetant (BAY3427080) Neurokinin 1 receptor antagonist; Neurokinin 3 receptor antagonist | TACR1, TACR3 | Phase 3 | Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer; Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women; Menopause-related Hot Flashes | Feb 2027 |
| Astellas | fezolinetant Neurokinin 3 receptor antagonist | TACR3 | Phase 3 | Hot Flashes; Prostate Cancer; Prostate CA; Vasomotor Symptoms … | Apr 2027 |
| Astellas | Fezolinetant Neurokinin 3 receptor antagonist | TACR3 | Phase 3 | Hot Flashes | Mar 2028 |
Hot Flashes (2) Prostate Cancer (2) Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer (1) Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women (1) Menopause-related Hot Flashes (1) Prostate CA (1) Vasomotor Symptoms (1) Breast Cancer Early Stage Breast Cancer (Stage 1-3) (1) Menopause (1)
small molecule (3)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.